Jubilant Pharmova (JUBLPHARMA.BO) Earnings Analysis
Jubilant Pharmova (JUBLPHARMA.BO) next reports earnings on 2026-07-23, consensus EPS 5.8 INR. Last quarter (2026-05-22) it beat with EPS 7.8 INR vs 7.45 INR est (+4.7%). It has beaten estimates in 5/6 recent quarters (83%). Trailing P/E 38.87.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does JUBLPHARMA.BO next report earnings?
| Next earnings date | 2026-07-23 |
|---|---|
| Consensus EPS estimate | 5.8 INR |
| Revenue estimate | 22.38B |
JUBLPHARMA.BO earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-22 | 7.8 INR | 7.45 INR | +4.7% | Beat |
| 2026-02-06 | 5 INR | 8.25 INR | -39.4% | Miss |
| 2025-10-31 | 7.8 INR | 6.85 INR | +13.9% | Beat |
| 2025-05-16 | 9.75 INR | 8.5 INR | +14.7% | Beat |
| 2025-01-31 | 7.3 INR | 6.1 INR | +19.7% | Beat |
| 2024-10-25 | 7.1 INR | 4.9 INR | +44.9% | Beat |
Beat rate: 5/6 (83%) over reported quarters with consensus data.
JUBLPHARMA.BO valuation and analyst view
| Trailing P/E | 38.87 |
|---|---|
| Trailing EPS | 25.198 INR |
| Price / book | 2.18 |
| Dividend yield | 0.51% |
| Market cap | 156.64B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is Jubilant Pharmova (JUBLPHARMA.BO)'s next earnings date?
Jubilant Pharmova is next scheduled to report on 2026-07-23, with a consensus EPS estimate of 5.8 INR and revenue estimate of 22.38B.
Did JUBLPHARMA.BO beat earnings last quarter?
In its 2026-05-22 report, JUBLPHARMA.BO posted EPS of 7.8 INR versus a 7.45 INR estimate — a beat of 4.7%.
What is JUBLPHARMA.BO's earnings track record?
Over the last 6 reported quarters with consensus data, JUBLPHARMA.BO beat estimates 5 times (83%).
What is JUBLPHARMA.BO's current P/E ratio and EPS?
JUBLPHARMA.BO trades at a trailing P/E of 38.87 on trailing EPS of 25.198234542764283 INR.
What do analysts rate JUBLPHARMA.BO?
JUBLPHARMA.BO has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.